BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver
New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation.
Expected to be released to CGT developers in August, the CryoCase is available for demonstration at this week's ISCT event in
The CryoCase is the first ever cryo-compatible rigid container designed for closed-system fill and retrieval for larger volumes of fluid (<75mL). The container is transparent, enabling improved end user compliance with USP 790, USP 1790, and other international visible inspection methods, and manufactured under strict environmental and processing controls designed to limit common sources of particulates in single-use disposable manufacturing. Early user testing has shown comparable cell viability and recovery for multiple cell types compared to storage in existing bags and drop testing in a frozen state demonstrates high resistance to leaks or fractures. Initial testing indicates that the CryoCase may materially reduce or eliminate particulates inherent in cryopreservation bags.
"Particulates in reagent manufacturing and final drug product is a growing problem that we believe can be reduced with better primary containers and true, closed-system approaches to CGT manufacturing," stated
CryoCase samples are now available for testing. Contact your
About
Media & Investor Relations
At the Company
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
(310) 691-7100
jcain@lhai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-introduces-the-cellseal-cryocase-at-international-society-for-cell--gene-therapies-isct-conference-in-vancouver-302157508.html
SOURCE